Stay updated with breaking news from Patrick Yu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SINGAPORE / ACCESSWIRE / May 26, 2021 / The global digital payment market is a structurally growing market. Recently, the importance and high growth of online channels have been adequately highlighted due to the impact of Covid-19.
Press release content from Business Wire. The AP news staff was not involved in its creation. GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye May 3, 2021 GMT Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire) Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire) PARIS--(BUSINESS WIRE)--May 3, 2021-- Regulatory News: Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Busi...
Patrick Yu "The fact that almost a third of the population describe themselves as racially prejudiced, almost half of young people have witnessed racist bullying in schools, and that these figures are rising not falling, suggests Stormont's racial equality strategy is failing," he said. Geraldine McGahey, Chief Commissioner at the Equality Commission, welcomed the report but added: "It is a concern that almost one in three people reported that they were prejudiced against people from minority ethnic communities and that this has increased since previous surveys. "It is important that there is...
Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the journal of the American Academy of Ophthalmology, Ophthalmology ® gene therapy in ND4 Leber Hereditary Optic Neuropathy (LHON) subjects. The paper*, published in the January issue under the title, “Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated with...
Experimental Therapy Injected in One Eye Unexpectedly Improves Vision in The Other 15 DECEMBER 2020 In a development that could restore sight to thousands of people with an inheritable condition called Leber's Hereditary Optic Neuropathy (LHON), scientists have been able to improve vision in both eyes in a majority of patients – even though only one eye was actually treated. The treatment is an experimental type of gene therapy, where tailored genetic material is injected to counteract genes that are defective or malfunctioning. With LHON, a m.11778G>A mutation in the MT-ND4 gene is t...